Crossref
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
Current Oncology · 2012
DOI: 10.3747//co.19.866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2012. Verfasst von A. Frost und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Frost, A., Mross, K., Steinbild, S., Hedbom, S., Unger, C., Kaiser, R., Trommeshauser, D., & Munzert, G. (2012). Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Current Oncology. https://doi.org/10.3747//co.19.866
Vancouver
Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Current Oncology. 2012. doi:10.3747//co.19.866
BibTeX
@article{Frost2012,
author = {Frost, A. and Mross, K. and Steinbild, S. and Hedbom, S. and Unger, C. and Kaiser, R. and Trommeshauser, D. and Munzert, G.},
title = {Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours},
journal = {Current Oncology},
year = {2012},
doi = {10.3747//co.19.866}
}
EUVIMED